Prescribing costs of hypoglycaemic agents and associations with metabolic control in Wales; a national analysis of primary care data.

Spend on hypoglycaemic agents is highly variable between practices and increased expenditure per patient is not associated with better glycaemic control. Whilst newer, more expensive agents have additional benefits, in individuals where these advantages are more marginal widespread use of these agents has important cost implications.